The Patent Finder

Lorus Therapeutics Inc.

Also on record
Records under this name other than patents Lorus Therapeutics Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Lorus Therapeutics Inc.

PatentTitleStatus Expires Confidence
US 9,309,2472-substituted imidazo[4,5-D]phenanthroline derivatives and their use in the treatment of cancer
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,080,739Aryl Imidazoles and Their Use as Anti-Cancer Agents
Formerly held
Term ended
Term ended Aug 9, 2025 · High confidence
Term endedTerm ended Aug 9, 2025High confidence
US 8,148,3922-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer
Formerly held
Lapsed on the fee record
Ended Apr 3, 2024 · From the USPTO record
Lapsed on the fee recordEnded Apr 3, 2024From the USPTO record
US 8,394,8152,4,5-trisubstituted imidazoles and their use as anti-microbial agents
Formerly held
Term ended
Ended no later than Aug 19, 2023 · From the USPTO record
Term endedEnded no later than Aug 19, 2023From the USPTO record
US 8,987,3052,4,5-trisubstituted imidazoles and their use as anti-microbial agents
Formerly held
Lapsed on the fee record
Ended Mar 24, 2023 · From the USPTO record
Lapsed on the fee recordEnded Mar 24, 2023From the USPTO record
US 8,969,372Aryl imidazoles and their use as anti-cancer agents
Formerly held
Lapsed on the fee record
Ended Mar 3, 2023 · Medium confidence
Lapsed on the fee recordEnded Mar 3, 2023Medium confidence
US 7,884,1202,4,5-trisubstituted imidazoles and their use as anti-microbial agents
Formerly held
Lapsed on the fee record
Ended Feb 8, 2023 · From the USPTO record
Lapsed on the fee recordEnded Feb 8, 2023From the USPTO record
US 8,287,851Use of interleukin 17E for the treatment of cancer
Formerly held
Lapsed on the fee record
Ended Oct 16, 2016 · From the USPTO record
Lapsed on the fee recordEnded Oct 16, 2016From the USPTO record
US 7,405,205Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
Formerly held
Lapsed on the fee record
Ended Jul 29, 2016 · From the USPTO record
Lapsed on the fee recordEnded Jul 29, 2016From the USPTO record
US 6,280,774Immunomodulating compositions from bile
Formerly held
Term ended
Term ended May 16, 2016 · From the USPTO record
Term endedTerm ended May 16, 2016From the USPTO record
10 of 22 patents shown.
Pro members see all 22.
Pro members: see all 22 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited